Dividends & Buybacks ·
At a special meeting on July 16, 2026, stockholders approved several key amendments to the Company's Restated…
OTLKOutlook Therapeutics, Inc.
At a special meeting on July 16, 2026, stockholders approved several key amendments to the Company's Restated Certificate of Incorporation. Shareholders authorized an increase in common stock from 260,000,000 to 600,000,000 shares. Additionally, voters approved the potential issuance of common stock underlying various private placement and placement agent warrants. Most significantly, stockholders approved an amendment to effect a reverse stock split with a ratio ranging from 1-for-10 to 1-for-50, to be determined by the board of directors. Outlook Therapeutics, Inc. is a biopharmaceutical company.